DFT study of structural, electronic, and spectroscopic properties of D6d endohedral fullerenes: X@C24H12 (X=Li+, Na+, K+).

S. Peng,Xiao Jun Li

DOI: https://doi.org/10.1016/j.saa.2009.01.016

2009-07-01

Abstract:

What problem does this paper attempt to address?

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression

Dana K Mitchell,Breanne Burgess,Emily White,Abbi E Smith,Elizabeth A Sierra Potchanant,Henry Mang,Brooke Rodriguez,Qingbo Lu,Shaomin Qian,Waylan Bessler,Xiaohong Li,Li Jiang,Kylee Brewster,Constance Temm,Andrew Horvai,Eric A Albright,Melissa L Fishel,Christine A Pratilas,Steven P Angus,D Wade Clapp,Steven D Rhodes,Dana K. Mitchell,Abbi E. Smith,Elizabeth A. Sierra Potchanant,Eric A. Albright,Melissa L. Fishel,Christine A. Pratilas,Steven P. Angus,D. Wade. Clapp,Steven D. Rhodes

DOI: https://doi.org/10.1158/1078-0432.ccr-23-2548

IF: 13.801

2023-12-23

Clinical Cancer Research

Abstract:Purpose: Plexiform neurofibromas (PNF) are benign peripheral nerve sheath tumors (PNST) associated with neurofibromatosis type 1 (NF1). Despite similar histological appearance, these neoplasms exhibit diverse evolutionary trajectories, with a subset progressing to malignant peripheral nerve sheath tumor (MPNST), the leading cause of premature death in individuals with NF1. Malignant transformation of PNF often occurs through development of atypical neurofibroma (ANF) precursor lesions characterized by distinct histopathological features and CDKN2A copy number loss. While genomic studies have uncovered key driver events promoting tumor progression, the transcriptional changes preceding malignant transformation remain poorly defined. Experimental Design: Here we resolve gene expression profiles in PNSTs across the neurofibroma-to-MPNST continuum in NF1 patients and mouse models, revealing early molecular features associated with neurofibroma evolution and transformation. Results: Our findings demonstrate that ANF exhibit enhanced signatures of antigen presentation and immune response, which are suppressed as malignant transformation ensues. MPNSTs further displayed deregulated survival and mitotic fidelity pathways, and targeting key mediators of these pathways, CENPF and BIRC5, disrupted growth and viability of human MPNST cells lines and primary murine Nf1-Cdkn2a mutant Schwann cell precursors. Finally, neurofibromas contiguous with MPNST manifested distinct alterations in core oncogenic and immune surveillance programs, suggesting that early molecular events driving disease progression may precede histopathological evidence of malignancy. Conclusions: If validated prospectively in future studies, these signatures may serve as molecular diagnostic tools to augment conventional histopathological diagnosis by identifying neurofibromas at high risk of undergoing malignant transformation, facilitating risk-adapted care.

oncology
Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma

Zhuowei Tian,Zhong Du,Guo Bai,Qiyu Gong,Yuanhe You,Guisong Xu,Jialiang Liu,Meng Xiao,Yanan Wang,Yue He

DOI: https://doi.org/10.1038/s41417-024-00727-1

IF: 5.854

2024-02-03

Cancer Gene Therapy

Abstract:Neurofibromatosis type 1 associated plexiform neurofibroma (pNF) is characterized by abundant fibroblasts and dense collagen, yet the intricate interactions between tumor-origin cells (Schwann cells) and neurofibroma-associated fibroblasts (NFAFs) remain elusive. Employing single-cell RNA sequencing on human pNF samples, we generated a comprehensive transcriptomics dataset and conducted cell-cell communication analysis to unravel the molecular dynamics between Schwann cells and NFAFs. Our focus centered on the pleiotrophin (PTN)/nucleolin (NCL) axis as a pivotal ligand-receptor pair orchestrating this interaction. Validation of PTN involvement was affirmed through coculture models and recombinant protein experiments. Functional and mechanistic investigations, employing assays such as CCK8, EdU, Western Blot, ELISA, Hydroxyproline Assay, and Human phospho-kinase array, provided critical insights. We employed siRNA or inhibitors to intercept the PTN/NCL/proline-rich Akt substrate of 40 kDa (PRAS40) axis, validating the associated molecular mechanism. Our analysis highlighted a subset of Schwann cells closely linked to collagen deposition, underscoring their significance in pNF development. The PTN/NCL axis emerged as a key mediator of the Schwann cell-NFAF interaction. Furthermore, our study demonstrated that elevated PTN levels enhanced NFAF proliferation and collagen synthesis, either independently or synergistically with TGF-β1 in vitro. Activation of the downstream molecule PRAS40 was noted in NFAFs upon PTN treatment. Crucially, by targeting NCL and PRAS40, we successfully reversed collagen synthesis within NFAFs. In conclusion, our findings unveil the pivotal role of the PTN/NCL/PRAS40 axis in driving pNF development by promoting NFAFs proliferation and function. Targeting this pathway emerges as a potential therapeutic strategy for pNF. This study contributes novel insights into the molecular mechanisms governing pNF pathogenesis.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas

Yuehua Li,Jun Liu,Jingxuan Huang,Chengjiang Wei,Lingling Ge,Manhon Chung,Beiyao Zhu,Zizhen Guo,Tingting Zheng,Haibo Li,Yihui Gu,Wei Wang,Qingfeng Li,Zhichao Wang

DOI: https://doi.org/10.1016/j.canlet.2024.217151

2024-09-01

Abstract:Plexiform neurofibromas (PNFs) are a prevalent and severe phenotype associated with NF1, characterized by a high teratogenic rate and potential for malignant transformation. The growth and recurrence of PNFs are attributed to aberrant proliferation and migration of Nf1-deficient Schwann cells. Protein tyrosine phosphatase receptor S (PTPRS) is believed to modulate cell migration and invasion by inhibiting the EMT process in NF1-derived malignant peripheral nerve sheath tumors. Nevertheless, the specific role of PTPRS in NF1-derived PNFs remains to be elucidated. The study utilized the GEO database and tissue microarray to illustrate a decrease in PTPRS expression in PNF tissues, linked to tumor recurrence. Furthermore, the down- and over-expression of PTPRS in Nf1-deficient Schwann cell lines resulted in the changes of cell migration and EMT processes. Additionally, RTK assay and WB showed that PTPRS knockdown can promote EGFR expression and phosphorylation. The restoration of EMT processes disrupted by alterations in PTPRS levels in Schwann cells can be achieved through EGFR knockdown and EGFR inhibitor. Moreover, high EGFR expression has been significantly correlated with poor prognosis. These findings underscore the potential role of PTPRS as a tumor suppressor in the recurrence of PNF via the regulation of EGFR-mediated EMT processes, suggesting potential targets for future clinical interventions.
Multi-dimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment

Lindy Zhang,Alexandre Maalouf,Stavriani C. Makri,Jineta Banerjee,Aditya Suru,Ada J. Tam,Ana Calizo,Kai Pollard,Jiawan Wang,Ludmila Danilova,Maria Ioannou,Adam S. Levin,Carol D. Morris,Daniel S. Rhee,Allan J. Belzberg,Jaishri O. Blakeley,Brian H. Ladle,Drew M. Pardoll,Calixto-Hope G. Lucas,Fausto J. Rodriguez,John M. Gross,Robert A. Anders,Christine A. Pratilas,Nicolas J. Llosa

DOI: https://doi.org/10.1158/1078-0432.ccr-24-1454

IF: 13.801

2024-09-27

Clinical Cancer Research

Abstract:Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for patients with MPNST have remained stagnant and most succumb to their disease; thus, novel therapeutic approaches are needed. A better understanding of the MPNST immune ecosystem will aid in the development of strategies to activate the immune system against the tumor. Herein, we profile the tumor immune microenvironment (TIME) in NF1-associated peripheral nerve sheath tumors (PNST) to discover insights on the role that tumor-infiltrating immune cells play in malignant transformation. Experimental design: Utilizing fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with NF1-PNST, we dissected the TIME by using immunohistochemistry, multiparameter flow cytometry, and comparative transcriptomic studies. Results: Immunophenotyping confirmed increased immune cells infiltration during malignant progression, with a predominance of infiltrating myeloid cells, particularly CD163+ tumor-associated macrophages (TAM). The T cells within MPNST exhibited signs of tumor activation, characterized by high PD-1 expression. Additionally, MPNST specimens demonstrated elevated levels of immunosuppressive TAM, with heightened PD-L1 expression. The proportion of CD163+ myeloid cells within the TIME correlated with poorer progression free survival. Notably, loss of H3K27 trimethylation correlated with low immune cell infiltration in MPNST. Conclusions: Malignant transformation of NF1-PNST is characterized by an immunosuppressive microenvironment comprising of TAM with high expression of PD-L1, which are associated with inferior outcomes. These findings suggest a clinical potential of immune modulating therapeutics that can unleash an anti-tumor immune response.

oncology
Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

Alyssa C Flint,Dana K Mitchell,Steven P Angus,Abbi E Smith,Waylan Bessler,Li Jiang,Henry Mang,Xiaohong Li,Qingbo Lu,Brooke Rodriguez,George E Sandusky,Andi R Masters,Chi Zhang,Pengtao Dang,Jenna Koenig,Gary L Johnson,Weihua Shen,Jiangang Liu,Amit Aggarwal,Gregory P Donoho,Melinda D Willard,Shripad V Bhagwat,D Wade Clapp,Steven D Rhodes,Alyssa C. Flint,Dana K. Mitchell,Steven P. Angus,Abbi E. Smith,George E. Sandusky,Andi R. Masters,Gary L. Johnson,Gregory P. Donoho,Melinda D. Willard,Shripad V. Bhagwat,D. Wade Clapp,Steven D. Rhodes

DOI: https://doi.org/10.1158/1078-0432.ccr-22-2854

IF: 13.801

2023-07-06

Clinical Cancer Research

Abstract:Purpose: Plexiform neurofibromas (PNF) are peripheral nerve sheath tumors that cause significant morbidity in persons with neurofibromatosis type 1 (NF1), yet treatment options remain limited. To identify novel therapeutic targets for PNF, we applied an integrated multi-omic approach to quantitatively profile kinome enrichment in a mouse model that has predicted therapeutic responses in clinical trials for NF1-associated PNF with high fidelity. Experimental Design: Utilizing RNA sequencing combined with chemical proteomic profiling of the functionally enriched kinome using multiplexed inhibitor beads coupled with mass spectrometry, we identified molecular signatures predictive of response to CDK4/6 and RAS/MAPK pathway inhibition in PNF. Informed by these results, we evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, and the ERK1/2 inhibitor, LY3214996, alone and in combination in reducing PNF tumor burden in Nf1flox/flox;PostnCre mice. Results: Converging signatures of CDK4/6 and RAS/MAPK pathway activation were identified within the transcriptome and kinome that were conserved in both murine and human PNF. We observed robust additivity of the CDK4/6 inhibitor, abemaciclib, in combination with the ERK1/2 inhibitor, LY3214996, in murine and human NF1(Nf1) mutant Schwann cells. Consistent with these findings, the combination of abemaciclib (CDK4/6i) and LY3214996 (ERK1/2i) synergized to suppress molecular signatures of MAPK activation and exhibited enhanced anti-tumor activity in Nf1flox/flox;PostnCre mice in vivo. Conclusion: These findings provide rationale for the clinical translation of CDK4/6 inhibitors alone and in combination with therapies targeting the RAS/MAPK pathway for the treatment of PNF and other peripheral nerve sheath tumors in persons with NF1.

oncology
EPCO-27. REVEALING TUMOR HETEROGENEITY AND IMMUNE MICROENVIRONMENT IN NF-1 GLIOMA BY SINGLE-CELL GENE EXPRESSION PROFILING

Fulvio D'Angelo,Luciano Garofano,Young Taek Oh,Ryan Najac,Michele Ceccarelli,Marica Eoli,Marc Sanson,Anna Lasorella,Antonio Iavarone

DOI: https://doi.org/10.1093/neuonc/noac209.461

2022-11-01

Neuro-Oncology

Abstract:Abstract Germline mutations in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF-1), the most common human genetic cancer predisposition syndrome. NF1 patients are prone to develop peripheral and central nervous system tumors, with glioma occurring in 15-20% of patients. The molecular profiles of glioma from patients with NF-1 have been previously explored by large scale DNA and RNA bulk analyses, providing the first comprehensive genetic landscape of NF-1 glioma. However, the intra-tumoral architecture and the microenvironment organization remained largely concealed within the global bulk profile. Here, to characterize the complexity of molecular states of both malignant and non-malignant cells, we profiled NF-1 glioma gene expression at individual cell resolution. We performed single-nuclei RNA sequencing (Nucseq) on frozen NF-1 glioma specimens, including high-grade and low-grade tumors. The functional classification of the transcriptional programs activated in the individual tumor cells identified three main molecular states that partially overlapped with the cellular subtypes of sporadic glioblastoma. Tumor cells of low-grade NF-1 glioma exhibited marked enrichment of neuronal functions, suggesting that the gliomagenesis process in the context of NF1 inactivation might be supported by specialized neuronal activities. Conversely, the proliferative state characterized high-grade NF-1 glioma, indicating that cell cycle-associated pathways are drivers of tumor progression. The single-cell deconvolution of immune microenvironment in NF-1 low grade glioma revealed infiltration of CD8+ T lymphocytes and the active crosstalk of these cells with pro-inflammatory macrophages and mature dendritic cells, supporting a possible anti-tumor cell-mediated response. The identification of divergent tumor cell states as well as the characterization of the immune infiltrates provide new insights for accurate stratification of NF-1 glioma patients and to inform personalized therapeutics.

oncology,clinical neurology
Distinctive mesenchymal-like neurofibroma stem cells shape NF1 clinical phenotypes controlled by BDNF microenvironment

Jingcun Shi,Zihui Yang,Yuhan Zhang,Ahmed Abdelrehem,Ziqian Wu,Bingqing Zhang,Meng Xiao,Shijian Zhang,Zhen Zhang,Lei Wang

DOI: https://doi.org/10.1016/j.tranon.2023.101852

IF: 4.803

2023-12-04

Translational Oncology

Abstract:Background Neurofibroma type I (NF1) often presents with multiple clinical phenotypes due to mutations of NF1 gene. The aim of this study was to determine the phenotypic and therapeutic relevance of tumor microenvironment in NF1 patients. Methods Tumor stem cells (TSCs) from NF1 were isolated and cultured using fluorescence activated cell sorting (FACS) and colony formation experiments. Then, flow cytometry was used to detect the surface markers, osteogenic and adipogenic differentiation were performed as well. Its tumorigenesis ability was confirmed by subcutaneous tumorigenesis in nude mice. Immunohistochemical staining was performed on neurofibroma tissues from the head and trunk with different phenotypes. The expression of BDNF in neurofibroma tissues was detected by Elisa and immunohistochemical staining. Western Blotting was used to detect the expression of p38 MAPK pathway in TSCs. The effect of BDNF neutralizing antibody on the tumorigenesis of TSCs was observed. Results Herein, we advocate that NF1 contain a new subgroup of mesenchymal-like neurofibroma stem cells (MNSCs). Such colony-forming MNSCs preserved self-renewal, multiple differentiation and tumorigenic capabilities. More interestingly, the MNSCs isolated from neurofibroma tissues of the same patient with different phenotypes presented site-specific capabilities. Moreover, different levels of brain-derived neurotrophic factor (BDNF) in neurofibroma tissues can impact the MNSCs by activating the TrkB/p38 MAPK pathway. Systemic administration of BDNF neutralizing antibodies inhibited MNSCs' characteristics. Conclusions We demonstrated that BDNF can modulate MNSCs and thereby controlling different tumor phenotypes between the head and trunk regions. Application of BDNF neutralizing antibodies may inhibit p38 MAPK pathway, therefore providing a promising strategy for managing NF1.

oncology
New from NPG: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

M. Swami

DOI: https://doi.org/10.1038/nm.2482

2011-09-07

Nature Network Boston

Abstract:
Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset

Jineta Banerjee,Yang Lyu,Stavriani C. Makri,Alexandra J. Scott,Lindy Zhang,Ana Calizo,Kai Pollard,Kuangying Yang,John M. Gross,Jiawan Wang,Adam S. Levin,Allan J. Belzberg,Carlos G. Romo,Robert J. Allaway,Jaishri O. Blakeley,Angela C. Hirbe,Christine A. Pratilas

DOI: https://doi.org/10.1101/2024.01.23.576977

2024-09-11

Abstract:Neurofibromatosis type 1 (NF1) is an inherited neurocutaneous condition that predisposes to the development of peripheral nerve sheath tumors (PNST) including cutaneous neurofibromas (CNF), plexiform neurofibromas (PNF), atypical neurofibromatous neoplasms with unknown biological potential (ANNUBP), and malignant peripheral nerve sheath tumors (MPNST). The successful advancement of therapeutic development for NF1-associated PNST necessitates the systematic acquisition and analysis of human tumor specimens and their corresponding model systems. RNA sequencing (RNAseq) and whole exome sequencing (WES) data were generated from 73 and 114 primary human tumor samples, respectively. These pre-processed data, standardized for immediate computational analysis, are accessible through the NF Data Portal, allowing immediate interrogation. This analysis combines new and previously released samples, offering a comprehensive view of the entire cohort sequenced. As a dedicated effort to systematically bank tumor samples from people with NF1, in collaboration with molecular geneticists and computational biologists to advance understanding of NF1 biology, the Johns Hopkins NF1 biospecimen repository offers access to samples and genomic data to promote advancement of NF1-related therapies.

Bioinformatics
Modeled Oceanic Response and Sea Surface Cooling to Typhoon Kai-Tak

Y. Tseng,S. Jan,D. Dietrich,I. Lin,Ya-Ting Chang,T. Tang

DOI: https://doi.org/10.3319/TAO.2009.06.08.02(IWNOP)

2010-02-01

Abstract:An ocean response to typhoon Kai-Tak is simulated using an accurate fourth-order, basin-scale ocean model. The surface winds of typhoon Kai-Tak were obtained from QuikSCAT satellite images blended with the ECMWF wind fields. An intense nonlinear mesoscale eddy is generated in the northeast South China Sea (SCS) with a Rossby number of O (1) and on a 50-100 km horizontal scale. Inertial oscillation is clearly observed. Advection dominates as a strong wind shear drives the mixed layer flows outward, away from the typhoon center, thus forcing upwelling from deep levels with a high upwelling velocity (＞ 30m day^(-1)). A drop in sea surface temperature (SST) of more than 9℃ is found in both observation and simulation. We attribute this significant SST drop to the influence of the slow moving typhoon, initial stratification and bathymetry-induced upwelling in the northeast of the SCS where the typhoon hovered.
Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

Jay Pundavela,Samantha Anne Dinglasan,Melissa Touvron,Sarah A. Hummel,Liang Hu,Tilat A. Rizvi,Kwangmin Choi,David A Hildeman,Nancy Ratner

DOI: https://doi.org/10.1126/sciadv.ado6342

IF: 13.6

2024-10-18

Science Advances

Abstract:Plexiform neurofibromas (PNFs) are benign nerve tumors driven by loss of the NF1 tumor suppressor in Schwann cells. PNFs are rich in immune cells, but whether immune cells are necessary for tumorigenesis is unknown. We show that inhibition of stimulator of interferon gene (STING) reduces plasma CXCL10, tumor T cell and dendritic cell (DC) recruitment, and tumor formation. Further, mice lacking XCR-1 + DCs showed reduced tumor-infiltrating T cells and PNF tumors. Antigen-presenting cells from tumor-bearing mice promoted CD8 + T cell proliferation in vitro, and PNF T cells expressed high levels of CCL5, implicating T cell activation. Notably, tumors and nerve-associated macrophages were absent in Rag1 −/− ; Nf1 f/f ; DhhCre mice and adoptive transfer of CD8 + T cells from tumor-bearing mice restored PNF initiation. In this setting, PNF shrunk upon subsequent T cell removal. Thus, STING pathway activation contributes to CD8 + T cell–dependent inflammatory responses required for PNF initiation and maintenance.

multidisciplinary sciences
Path-25. Consensus Recommendations For An Integrated Diagnostic Approach To Nerve Sheath Tumors Arising In The Setting Of Neurofibromatosis Type 1

Carina Dehner,Andrea Gross,Alexander Lazar,Calixto-Hope Lucas,Markku Miettinen,Melike Pekmezci,Arie Perry,Martha Quezado,Fausto Rodriguez,Carlos Romo,Anat Stemmer-Rachamimov,David Viskochil

DOI: https://doi.org/10.1093/neuonc/noae165.0724

2024-11-29

Neuro-Oncology

Abstract:NF1-associated nerve sheath tumors exist on a morphologically and molecularly diverse spectrum. Criteria for diagnosing neurofibroma, atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP), and malignant peripheral nerve sheath tumor (MPNST) developed by consensus in 2017 were codified in recent WHO guidelines. However, incorporation of molecular strata should be formalized to aid in early identification and appropriate intervention for patients with lesions at increased risk for malignant transformation. Here, we assembled a multi-institutional expert pathology working group to review molecular literature and formalize classification recommendations. In collaboration with clinical/surgical, imaging, and pre-clinical working groups during the "Symposium on Atypical Neurofibroma: State of the Science" held April 2024, we reached consensus on a potential integrated diagnostic approach. Based on strong preclinical and clinical evidence, we propose CDKN2A homozygous deletion as a sufficient molecular feature for diagnosing ANNUBP and either SUZ12 , EED , or TP53 inactivating mutations or significant aneuploidy as sufficient molecular features for diagnosing MPNST, even in the absence of high-grade histologic features. In the absence of MPNST-defining molecular alterations, we also recommend reclassifying "low grade MPNST" as "ANNUBP with increased proliferation". To facilitate molecular characterization of concerning tumors, we recommend at least six core biopsies be obtained and divided into two cores per block at time of grossing. Worrisome immunohistochemical features including reduced SOX10 or S100 immunoreactivity, decreased CD34 lattice-like network, minimal p16 expression, loss of H3K27me3 immunoreactivity, p53 overexpression, and increased Ki-67 labeling can guide region selection. A comprehensive next-generation sequencing panel that includes copy number and zygosity assessment is the preferred single assay, though a combination of multiple molecular techniques may provide similar information. In the spirit of the prior 2017 consensus agreement, we hope this refined integrated diagnostic approach for NF1-associated nerve sheath tumors will continue to evolve alongside our understanding of the spectrum of these neoplasms.

oncology,clinical neurology
Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1

Ilenia Rita Cannizzaro,Mirko Treccani,Antonietta Taiani,Enrico Ambrosini,Sabrina Busciglio,Sofia Cesarini,Anita Luberto,Erika De Sensi,Barbara Moschella,Pierpacifico Gismondi,Cinzia Azzoni,Lorena Bottarelli,Giovanna Giordano,Domenico Corradi,Enrico Maria Silini,Valentina Zanatta,Federica Cennamo,Patrizia Bertolini,Patrizia Caggiati,Davide Martorana,Vera Uliana,Antonio Percesepe,Valeria Barili

DOI: https://doi.org/10.3390/ijms251910822

IF: 5.6

2024-10-09

International Journal of Molecular Sciences

Abstract:Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder characterized by the predisposition to develop tumors such as malignant peripheral nerve sheath tumors (MPNSTs) which represents the primary cause of death for NF1-affected patients. Regardless of the high incidence and mortality, the molecular mechanisms underneath MPNST growth and metastatic progression remain poorly understood. In this proof-of-concept study, we performed somatic whole-exome sequencing (WES) to profile the genomic alterations in four samples from a patient with NF1-associated MPNST, consisting of a benign plexiform neurofibroma, a primary MPNST, and metastases from lung and skin tissues. By comparing genomic patterns, we identified a high level of variability across samples with distinctive genetic changes which allow for the definition of profiles of the early phase with respect to the late metastatic stages. Pathogenic and likely pathogenic variants were abundant in the primary tumor, whereas the metastatic samples exhibited a high level of copy-number variations (CNVs), highlighting a possible genomic instability in the late phases. The most known MPNST-related genes, such as TP53 and SUZ12, were identified in CNVs observed within the primary tumor. Pathway analysis of altered early genes in MPNST pointed to a potential role in cell motility, division and metabolism. Moreover, we employed survival analysis with the TCGA sarcoma genomic dataset on 262 affected patients, in order to corroborate the predictive significance of the identified early and metastatic MPNST driver genes. Specifically, the expression changes related to the mutated genes, such as in RBMX, PNPLA6 and AGAP2, were associated with reduced patient survival, distinguishing them as potential prognostic biomarkers. This study underlines the relevance of integrating genomic results with clinical information for early diagnosis and prognostic understanding of tumor aggressiveness.

biochemistry & molecular biology,chemistry, multidisciplinary
Conditional deletion of Pten tumor suppressor gene and activation of K Ras oncogene result in the development of Neurofibromatoses

Caroline Gregorian,Jonathan Nakashima,Annie Liu,Matthias Groszer,Rachel Kim,Paul Mischel,Michael Sofroniew,Xin Liu,Hong Wu

2007-01-01

Abstract:3863Neurofibromatoses (NFs) are a set of inherited disorders designated as Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, that result in a variety of tumors in the central and peripheral nervous systems (CNS and PNS). NF1 and NF2 are caused by mutations in the neurofibromin (Nf1) or neurofibromin-2 (Nf2, or merlin) gene, respectively, which act as negative regulators of RAS activity. Nf1+/-, Nf2+/-, and conditional knockout lines for either gene fail to recapitulate the full disease spectrum observed in humans. To address the involvement of other signaling pathways with those controlled by NF1 and NF2, we utilized Cre-Lox technology to perturb RAS/RAF/MAPK and PI3K/AKT/mTOR, two of the major signaling pathways involved in tumorigenesis of the nerve system, individually and in combination. The resulting mouse model accurately reflects the human clinical …
ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors

Reinhard E Friedrich,Louisa K N Nörnberg,Christian Hagel,REINHARD E. FRIEDRICH,LOUISA K. N. NÖRNBERG,CHRISTIAN HAGEL

DOI: https://doi.org/10.21873/anticanres.15712

2022-04-30

Anticancer Research

Abstract:AIM: To characterize the growth pattern and antigen profile of peripheral nerve sheaths tumors (PNST) in a large series of tumors obtained from patients with neurofibromatosis type 1 (NF1).MATERIALS AND METHODS: Tissue micro-array technique was applied to study 520 PNSTs of 385 patients with NF1 by immunohistochemistry for human epidermal growth factor receptors erb-b2 receptor tyrosine kinase 2 (ERBB2) and ERBB3, CD44, neuroregulin (NRG1) and proliferation index by Ki-67. PNSTs were classified as cutaneous neurofibroma (CNF) in 114 cases, diffuse neurofibroma (DNF) in 109, diffuse plexiform neurofibroma (DPNF) in 108, plexiform neurofibroma (PNF) in 110, and malignant PNST (MPNST) in 22.RESULTS: The Ki-67 proliferation index was significantly higher in MPNST than in benign PNST (p<0.001). ERBB2 expression was significantly lower in PNST with diffuse growth than in PNF and MPNST (p<0.001). ERBB3 expression was also higher in PNF and MPNST (both p<0.001) than in diffuse PNST. NRG1 expression was significantly higher in PNF than in non-encapsulated benign PNST or MPNST (both p<0.001). Co-expression of ERBB2, ERBB3 and ligand NRG1 was rare, mainly observed in PNST with a plexiform component (in four PNFs, nine DPNFs, one CNF, and two MPNSTs). Expression of CD44 in contrast was significantly stronger in diffusely growing PNST than in PNF (p<0.001).CONCLUSION: Growth factor receptors ERBB2 and ERBB3 were significantly up-regulated in PNF and MPNST. The antigen expression pattern of DPNF resembled that of benign PNST with diffuse growth pattern rather than that of encapsulated PNF. Differentiating PNST may be important for the assessment of neurofibroma progression, and for the expected impact of drugs currently used for tumor reduction.

oncology
Plexiform Neurofibroma Without Neurofibromatosis Type 1

Uwe Wollina,Jacqueline Schönlebe

Abstract:Dear Editor, Plexiform neurofibroma (PNF) is a particular subtype of benign nerve sheath tumors with a reticular growth pattern not respecting tissue borders and involving several nerve branches or fascicles. It is most commonly reported in patients with neurofibromatosis type-1 (NF-1) and represents in up to 30% of NF-1 patients (1,2). Other possible associations include schwannomatosis, multiple cutaneous schwannomas syndrome, and rarely neurofibromatosis type-2 (NF-2) (3). PNF develops as a result of tumor proliferation to all parts of the peripheral nervous system. It may cause functional and cosmetic impairment, pain, and a certain risk of malignant transformation in internal organs in some critical cases (4,5). Malignant peripheral nerve sheath tumors occur in about 10% of NF-1 patients (4,5). NF-1 is caused by mutations in the NF-1 tumor-suppressor gene, which encodes a GTPase-Activating Protein (GAP) that negatively regulates p21-RasNF1 (6). These patients have a predisposition to develop both benign and malignant tumors (6). Isolated or NF-1-associated cutaneous or superficial PNF, however, do not transform into their malignant counterpart (1). We report an isolated case of a plexiform PNF in a 16-year-old girl without NF-1. A-16-year-old Caucasian woman presented with a slow-growing exophytic nodule on her right flank. The tumor was asymptomatic, and tumor removal was requested for esthetic reasons. The patient was otherwise healthy. Her family history was negative for hereditary disorders. She was taking no medications at the time. On examination, a 1.8×1.6 cm large, slow-growing, and asymptomatic exophytic asymptomatic tumor was observed on the right flank (Figure 1). The primary suspicion was a complex nevus tumor type such as nevus sebaceous or nevus lipomatosus. The tumor was surgically removed, and the defect was closed by tissue expansion. Histology revealed a spindle-cell proliferation of S-100 positive cells without cellular atypia and myxoid stroma (Figure 2). The diagnosis of PNF was thus established. Healing was uneventful. There were no clinical signs of NF-1 or NF-2. We reported a case of PNF without NF-1 or NF-2. The diagnosis of an isolated PNF is a very rare event (7-10). In a large study from Lima lasting 33 years, only one isolated PNF not associated with NF-1 was observed. In this patient, PNF developed in the oral mucosa (7). An isolated PNF causing an auricular deformity has been previously observed in a 14-year-old boy (8). In India, a 11-year-old girl with an isolated PNF of the tongue was reported (9). Isolated PNFs are not necessarily limited to children and adolescents but may also occur later in life (10). The gold standard of treatment is surgical intervention. In case of unresectable and painful tumors, interferon alfa is a medical option (11). Other drugs are under evaluation, such as oral selumetinib, a selective inhibitor of MAPK kinase 1 and 2, AZD8055, an ATP-competitive "active-site" mTOR inhibitor, or a BromoDomain-containing protein 4-inhibitor (12,13). In conclusion, isolated PNF is a very rare observation. In case of impairment, surgery - whenever possible - is the preferred treatment option (8).
Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Jun Liu,Jing-Ning Huang,Ming-Han Wang,Zhen-Yang Ni,Wei-Hao Jiang,Manhon Chung,Cheng-Jiang Wei,Zhi-Chao Wang

DOI: https://doi.org/10.3389/fonc.2022.898971

IF: 4.7

2022-05-24

Frontiers in Oncology

Abstract:Neurofibromatosis type 1 (NF1) is a dominant hereditary disease characterized by the mutation of the NF1 gene, affecting 1/3000 individuals worldwide. Most NF1 patients are predisposed to benign peripheral nerve sheath tumors (PNSTs), including cutaneous neurofibromas (CNFs) and plexiform neurofibromas (PNFs). However, 5%-10% of PNFs will ultimately develop into malignant peripheral nerve sheath tumors (MPNSTs), which have a poor prognosis. Early and reliable differentiation of benign and malignant tumors in NF1 patients is of great necessity. Pathological evaluation is the "gold standard" for a definite diagnosis, but the invasive nature of the biopsy procedure restricts it from applying as a screening tool during the decades-long follow-up of these patients. Non-invasive image-based diagnostic methods such as CT and MRI are often considered essential screening tools for multiple types of tumors. For NF1 patients' lifelong regular follow-ups, these radiological methods are currently used for tumor evaluation. However, no consensus was established on screening the malignant transformation of benign PNSTs. Moreover, novel technologies like radiogenomics and PET-MRI have not been well evaluated and fully adopted for NF1 patients. This review summarizes current studies of different imaging methods for differentiating benign and malignant tumors in NF1. Meanwhile, we discussed the prospects of the usage of new tools such as radiogenomics and PET-MRI to distinguish MPNST from benign PNSTs more precisely. Summarizing these findings will help clarify the directions of future studies in this area and ultimately contribute to the radiology images-based clinical screening of MPNST in NF1 patients and finally improve the overall survival rates of these patients.

oncology
Translating current basic research into future therapies for neurofibromatosis type 1

Jean-Philippe Brosseau,Chung-Ping Liao,Lu Q Le

DOI: https://doi.org/10.1038/s41416-020-0903-x

Abstract:Neurofibromatosis type 1 (NF1) is a hereditary tumour syndrome that predisposes to benign and malignant tumours originating from neural crest cells. Biallelic inactivation of the tumour-suppressor gene NF1 in glial cells in the skin, along a nerve plexus or in the brain results in the development of benign tumours: cutaneous neurofibroma, plexiform neurofibroma and glioma, respectively. Despite more than 40 years of research, only one medication was recently approved for treatment of plexiform neurofibroma and no drugs have been specifically approved for the management of other tumours. Work carried out over the past several years indicates that inhibiting different cellular signalling pathways (such as Hippo, Janus kinase/signal transducer and activator of transcription, mitogen-activated protein kinase and those mediated by sex hormones) in tumour cells or targeting cells in the microenvironment (nerve cells, macrophages, mast cells and T cells) might benefit NF1 patients. In this review, we outline previous strategies aimed at targeting these signalling pathways or cells in the microenvironment, agents that are currently in clinical trials, and the latest advances in basic research that could culminate in the development of novel therapeutics for patients with NF1.
Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018–2019

Yoshua Colyn Collins‐Sawaragi,Rosalie Ferner,Grace Vassallo,Germana De Agrò,Simon Eccles,Jill Cadwgan,Darren Hargrave,Eileen Hupton,Judith Eelloo,Lauren Lunt,Vivian Tang,Emma Burkitt Wright,Karine Lascelles

DOI: https://doi.org/10.1002/ajmg.a.62691

2022-02-18

American Journal of Medical Genetics Part A

Abstract:We report on the location, symptoms, and management of plexiform neurofibroma (PN) in children with Neurofibromatosis Type 1 (NF1) attending the 2 National Complex Neurofibromatosis 1 Services at Guy's and St. Thomas' NHS Foundation Trust, London and St Mary's Hospital, Manchester. Retrospective data collection was performed from patient chart reviews from April 2018 to April 2019. There were 127 NF1 patients with PN, age range 0.8-17.0, mean age was 9.9 years (SD ± 4.2 years). The main location of the PN was craniofacial in 35%, and limb in 19%. Disfigurement was present in 57%, pain in 28%, impairment of function in 23%, and threat to function in 9% of children. Fifty-four percent of patients were managed conservatively, 28% surgically, and 19% are either taking or due to start a mitogen-activated protein kinase kinase (MEK) inhibitor (selumetinib or trametinib), either through a clinical trial or compassionate usage scheme. This national study provides a comprehensive overview of the management of children with PN in an era where new therapies (MEK inhibitors) are becoming more widely available. We anticipate that there will be a shift to more patients receiving MEK inhibitor therapy and combination therapy (surgery and MEK inhibitor) in the future.

genetics & heredity
EPCO-04. SPATIAL TRANSCRIPTOMIC ANALYSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS REVEALS THERAPEUTICALLY TARGETABLE MOLECULAR SIGNATURES IN REGIONS UNDERGOING HISTOPATHOLOGIC TRANSFORMATION

Kanish Mirchia,Soo-Jin Cho,Alyssa T Reddy,Line Jacques,Melike Pekmezci,Arie Perry,David Raleigh,Harish Vasudevan

DOI: https://doi.org/10.1093/neuonc/noad179.0469

2023-11-01

Neuro-Oncology

Abstract:Abstract Malignant peripheral nerve sheath tumors (MPNSTs) evolve from plexiform neurofibromas (pNF) in patients with neurofibromatosis type-1 (NF-1) yet the cellular and transcriptomic mechanisms underlying this transformation remain unclear. Here, we perform spatial gene expression profiling on fifteen MPNSTs to correlate histologic observations with transcriptomic programs and identify mechanisms underlying malignant transformation. METHODS: Fifteen MPNSTs, including tumors with a histopathologically defined transition zone between adjacent low-grade and high-grade areas (n=3), were retrospectively identified. Spatial transcriptomic profiling was performed using Visium followed by downstream processing with SpaceRanger, Seurat, Harmony, and monocle. RESULTS: 50,807 unique spatial transcriptomes were distributed across 17 unique clusters, of which 12 were enriched for tumor cells and 5 for non-tumor microenvironment cells based on histologic evaluation, unsupervised cell-type assignment, marker gene expression, and cell signature gene sets. Transcriptomic clusters in low-grade areas were enriched for genes regulating mononuclear cell migration and cell-cell adhesion, while high-grade regions were enriched for Ras/Raf/MEK/ERK target genes, anti-apoptotic programs, and extracellular matrix reorganization genes. Trajectory inference beginning in low grade regions revealed spatially organized molecular signatures of malignant transformation enriched for cell cycle progression within histopathologically homogeneous regions. Moreover, the intermediate transformation zone between low-grade neurofibromatous and high-grade MPNST histopathologic regions was marked by loss of cell differentiation genes and increased cell cycle progression. CONCLUSIONS: Spatial transcriptomic analysis elucidates the cellular and gene expression patterns underlying progression from pNF to MPNST. Distinct cell populations exist across low-grade, transformation zone, and high-grade regions in MPNSTs highlighted by alterations in Ras/Raf/MEK/ERK signaling, cell differentiation and cell cycle programs, shedding light on targets for combinatorial molecular therapy to decrease the risk of malignant transformation and serving as a biomarker of aggressive peripheral nerve tumors to complement conventional histopathology.

oncology,clinical neurology

DFT study of structural, electronic, and spectroscopic properties of D6d endohedral fullerenes: X@C24H12 (X=Li+, Na+, K+).

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression

Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma

Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas

Multi-dimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment

Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

EPCO-27. REVEALING TUMOR HETEROGENEITY AND IMMUNE MICROENVIRONMENT IN NF-1 GLIOMA BY SINGLE-CELL GENE EXPRESSION PROFILING

Distinctive mesenchymal-like neurofibroma stem cells shape NF1 clinical phenotypes controlled by BDNF microenvironment

New from NPG: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset

Modeled Oceanic Response and Sea Surface Cooling to Typhoon Kai-Tak

Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

Path-25. Consensus Recommendations For An Integrated Diagnostic Approach To Nerve Sheath Tumors Arising In The Setting Of Neurofibromatosis Type 1

Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1

Conditional deletion of Pten tumor suppressor gene and activation of K Ras oncogene result in the development of Neurofibromatoses

ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors

Plexiform Neurofibroma Without Neurofibromatosis Type 1

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Translating current basic research into future therapies for neurofibromatosis type 1

Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018–2019

EPCO-04. SPATIAL TRANSCRIPTOMIC ANALYSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS REVEALS THERAPEUTICALLY TARGETABLE MOLECULAR SIGNATURES IN REGIONS UNDERGOING HISTOPATHOLOGIC TRANSFORMATION